PT - JOURNAL ARTICLE AU - William T. Lee AU - Roxanne C. Girardin AU - Alan P. Dupuis II AU - Karen E. Kulas AU - Anne F. Payne AU - Susan J. Wong AU - Suzanne Arinsburg AU - Freddy T. Nguyen AU - Damodara Rao Mendu AU - Adolfo Firpo-Betancourt AU - Jeffrey Jhang AU - Ania Wajnberg AU - Florian Krammer AU - Carlos Cordon-Cardo AU - Sherlita Amler AU - Marisa Montecalvo AU - Brad Hutton AU - Jill Taylor AU - Kathleen A. McDonough TI - Neutralizing Antibody Responses in COVID-19 Convalescent Sera AID - 10.1101/2020.07.10.20150557 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.10.20150557 4099 - http://medrxiv.org/content/early/2020/07/11/2020.07.10.20150557.short 4100 - http://medrxiv.org/content/early/2020/07/11/2020.07.10.20150557.full AB - Passive transfer of antibodies from COVID-19 convalescent patients is being used as an experimental treatment for eligible patients with SARS-CoV-2 infections. The United States Food and Drug Administration’s (FDA) guidelines for convalescent plasma recommends target antibody titers of 160. We evaluated SARS-CoV-2 neutralizing antibodies in sera from recovered COVID-19 patients using plaque reduction neutralization tests (PRNT) at low (PRNT50) and high (PRNT90) stringency thresholds. We found that neutralizing activity increased with time post symptom onset (PSO), reaching a peak at 31-35 days PSO. At this point, the number of sera having neutralizing titers of at least 160 was ∼93% (PRNT50) and ∼54% (PRNT90). Sera with high SARS-CoV-2 antibody levels (>960 ELISA titers) showed maximal activity, but not all high titer sera contained neutralizing antibody at FDA recommended levels, particularly at high stringency. These results underscore the value of serum characterization for neutralization activity.Competing Interest StatementMount Sinai Hospital is in the process of licensing assays to commercial entities based on the assays described here and has filed for patent protection.Funding StatementTesting at the Wadsworth Center was supported by internal funding at the New York State Department of Health. Mount Sinai Hospital is a CLIA laboratory and all the testing for patient specimens was supported by reimbursement from insurance policies.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Specimens were collected with informed consent obtained from individuals in accordance with guidelines of Mount Sinai Hospital (MSH) and the Westchester County Department of Health (WCDH). Testing at the Wadsworth Center was done under a declared Public Health Emergency with a waiver from the NYSDOH Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript is freely available.FDAFood and Drug AdministrationPRNTplaque reduction neutralization testPSOpost-symptom onsetCOVID-19Coronavirus Disease 2019SARS-CoV-2Severe Acute Respiratory Syndrome coronavirus 2AbantibodyMNmicroneutralizationMSHMount Sinai HospitalWCDHWestchester County Department of HealthELISAenzyme-linked immunosorbent assayMIAmicrosphere immunoassayNnucleocapsid proteinRBDreceptor-binding domain of the spike protein